Business briefs: Amgen and Wockhardt

Share this article:

Rebounding from its failed Onyx courtship, Amgen announced Tuesday that it has paired up with Servier in a deal that will give it some heft in the cardiovascular space. The collaboration, which garners a $50-million signing fee for Servier, gives Amgen commercial rights to the oral chronic heart failure drug ivabradine, which is approved in the EU under the brand name Procoralan, as well as the exclusive option to develop Servier's S38844, a Phase II heart failure drug. In exchange, Servier scored rights to commercialize Amgen's Phase II heart failure drug omecamtiv in Europe. 

Indian generic drug maker Wockhardt has been locked out of European drug markets. Bloomberg reports that the drug maker's Waluj factory failed to meet UK guidelines. The FDA shut down the company's US distribution from this same plant in May, a move Bloomberg said is forecast to cost the manufacturer around $100 million in sales.

Share this article:

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.